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Background: Medications necessary for disease management can simultaneously contribute to weight gain,
especially in children. Patients with preexisting obesity are more susceptible to medication-related weight gain.
How equipped are primary care practitioners at identifying and potentially reducing medication-related weight
gain? To inform this question germane to public health we sought to identify potential gaps in clinician knowledge
related to metabolic adverse drug effects of weight gain.
Methods: The study analyzed practitioner responses to the pre-activity questions of six continuing medical
education (CME) activities from May 2009 through August 2010.
Results: The 20,705 consecutive, self-selected respondents indicated varied levels of familiarity with adverse
metabolic effects and psychiatric indications of atypical antipsychotics. Correct responses were lower than predicted
for drug indications pertaining to autism (−17% predicted); drug effects on insulin resistance (−62% predicted);
chronic disease risk in mental illness (−34% predicted); and drug safety research (−40% predicted). Pediatrician
knowledge scores were similar to other primary care practitioners.
Conclusions: Clinicians’ knowledge of medication-related weight gain may lead them to overestimate the benefits
of a drug in relation to its metabolic risks. The knowledge base of pediatricians appears comparable to their
counterparts in adult medicine, even though metabolic drug effects in children have only become prevalent
recently.
Keywords: Medication effects on appetite, Insulin resistance, Drug-related weight gain, Mental illness as a risk factor
for obesity, Adverse metabolic drug effects, Drug safety research, Nutrition knowledge of primary care practitionersBackground
No study to date assesses the knowledge base around
medication-related weight gain in pediatric or adult pri-
mary care medicine. We therefore sought to characterize
what practitioners know about metabolic drug effects in
the context of clinical decision-making.
Informed clinicians can often modify their patients’
risk of adverse metabolic drug effects, even when medi-
cations are essential for disease management [1]. Practi-
tioners can choose lowest effective dosing and therapies
with fewer metabolic effects; treat underlying medical* Correspondence: kohlstadt@outlook.com
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distribution, and reproduction in any mediumconditions which can contribute to weight gain, such as
sleep apnea and hypothyroidism; correct nutritional defi-
ciencies such as vitamins B12 [2] and D [3] to facilitate
lifestyle adherence; and counsel patients on drug-related
increases in appetite, emphasizing adherence to medica-
tion and healthful lifestyle choices.
Among the patient groups most vulnerable to metabolic
drug effects are children. Children are more susceptible to
central nervous system effects of medications [4]. Some
metabolic drug effects are unique to children at certain
growth stages and demonstrate a prolonged effect [5,6].
Metabolic drug effects also tend to be delayed relative to
the therapeutic benefit, especially in children. Concur-
rently, drug exposure is increasing in children, the age
group with the fastest growing number of prescriptionsed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Preexisting overweight and obesity heighten vulnerability
to metabolic drug effects.
Managing adverse metabolic drug affects is relatively
new to the practice of pediatrics. Historically pediatricians
focused on medication-related weight loss and stunting,
recorded as step-offs on patient growth charts. Today’s
pediatric practice may require as diligent a diagnosis and
management of medication-related weight gain, especially
since preexisting overweight and obesity, defined as a body
mass index at or above the 85th percentile, has reached ap-
proximately 32% of the U.S. population ages 2-19 [8,9].
Disseminating drug safety updates to pediatricians holds
other challenges as well. Safety information specific to
children represents a recent advance. Practitioners may
not realize they need to watch for such updates [10].
Metabolic drug effects specific to children and adolescents
may be first identified years after a drug is on the market
[11] because the metabolic effects in children tend to
manifest beyond the timeframe of clinical trials. Dissemin-
ating drug safety information may be additionally compli-
cated by practice patterns. For example, psychiatrists may
diagnose and prescribe highly specialized treatment and
look to primary care practitioners to monitor patients for
adverse drug effects.
Clinicians draw on their knowledge base of adverse
metabolic drug effects for clinical decision-making. Ele-
vated and unique risks of metabolic drug effects and
major shifts in disease prevalence and practice patterns in
pediatrics together prompted our interest in confirming
that primary care clinicians who care for children have a




Continuing medical education (CME) activities were de-
veloped in partnership with CME providers. Inclusion
criteria for partners were: experience implementing pre-
activity questions, having primary care practitioners as a
target audience, willingness to co-develop programs rele-
vant to medication-associated weight gain, providing free
public access to associated media and print materials,
and collaborating within time and budget constraints.
Partners were selected across different media - audio, lec-
tures, or web-based activities - Audio-Digest Foundation,
Medscape CME, The Maryland Academy of Family Physi-
cians, and The FDA Scientific Rounds Program.
Instrument development
The instrument in this study, pre-CME activity ques-
tions, measures practitioners’ baseline knowledge rele-
vant to the content of the CME activities. Pre-activity
questions were 4-choice multiple choice questions ortrue-false questions. They were directed at clinical
decision-making and were organized into four categories:
1) drug indications, 2) metabolic drug effects, 3) drug
safety updates, and 4) patients most at risk. Each CME
program partner selected among the pre-activity questions
and adapted the wording to their standard format.CME content
The 6 CME activities pertained to either atypical anti-
psychotic use in children or obesogenic medications in
general. They were provided through the CME partners at
varied intervals between June 2009 and August 2010. Each
activity was an audio program, web-based program, or
conference lecture; and awarded a maximum of 0.5 to 2
Category 1 CME credits. The program content, partici-
pant characteristics, and pre-activity questions are
presented in Table 1.
In order to compare the knowledge of practitioners spe-
cializing in pediatrics with adult medicine practitioners,
we developed Activity 5 which is applicable to the care of
children and adults.
Activity 6 was the only program where the target audi-
ence was not primary care practitioners. The biweekly ac-
tivity is attended by a diverse group of health care
practitioners and scientists, all of whom work in regula-
tion. The activity was included to better characterize prac-
titioner knowledge of the autism indication for atypical
antipsychotics.Response analysis
The information used for the response analysis was
obtained from the CME providers as anonymized source
data with no way to match responses with individuals.
No personal identifiers were used. The respondents were
participating in CME activities, where responses to the
related learning questions are routinely aggregated to in-
form future CME development and related research.
We analyzed the data with and without comparing it
to predicted scores. Predicted scores facilitate compari-
son between multiple choice questions with four choices
and binomial true-false questions, which differ in the
likelihood of selecting a correct answer by chance alone.
For this analysis, predicted scores were 70% for multiple
choice and 85% for true-false questions. The basis for
these numbers comes from Audio-Digest’s overall average
pretest scores, which are 70%, [personal communication
August 2010] and the pedagogic intent of a CME to build
on participants’ existing practice-relevant knowledge.
Each response holds an inherent error, since a partici-
pant with a constant knowledge base could score better or
worse on the pre-activity depending on the circumstances
at that moment. We estimated the two-tailed two standard
deviations of this variability to be ten percent. We also
Table 1 Summary of continuing medical education (CME) programs, June 2009 – August 2010
CME partner and activity Date, audience and promotions Pre-activity questions
Activity 1: Maryland Academy of Family
Physicians, 2009 Annual CME Assembly;
Drug –nutrient interactions
6/09 Conference attendees, primarily family
physicians in the mid-Atlantic
5 interspersed questions using an audience
response system
Activity 2: Audio-Digest Pediatrics on
Atypical antipsychotics in children
8/09-8/10 Subscribers, practitioners who care
for children, approximately 75% physicians
10 questions submitted by mail, fax, or website
Activity 3: Audio-Digest Special Topics on
Atypical antipsychotics in children *
8/09-8/10 Responders to free CME post on the
Audio-Digest homepage; American Academy
of Pediatrics newsletter feature
10 questions submitted via website
Activity 4: Medscape CME on
Atypical antipsychotics in children *
11/09-1/10 Participants in Medscape’s Psychiatry
and Mental Health listserv with multiple cross-posts
6 web-based interspersed questions
Activity 5: Medscape CME on
Medication-related weight gain *
5/10-8/10 Participants in Medscape’s Preventive
Medicine and Public Health listserv with multiple
cross-posts; American College of Preventive
Medicine feature
4 web-based interspersed questions
Activity 6: Food and Drug Administration
Scientific Rounds on Autism
5/10 FDA employees with regulatory and
clinical interests
3 questions using an audience response system,
1 which was developed to better understand
responses from prior CME programs
*Three of the activities may be viewed online [12-14].
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fied as close to correct, also called the second best answer.
STATAW statistical software was used to run discrete-
response regression analyses on pre-activity question re-
sponses. Probit regressions were used for binomial
dependent variables, analyzing whether the respondent
answered the CME question correctly. The probit models
give a standard normal z-score rather than a t-statistic,
with the total variability explained as a pseudo-R2 rather
than a normal R2. McFadden’s pseudo-R2 is reported. The
probit analysis reports the overall significance of the
model using an LR chi-square. The effect of a control vari-
able in predicting correct responses (a certain percentage
above/below the average) is calculated as the difference in
probability of getting a question correct versus a baseline
probability. For this analysis, baseline probability is where
all control variables are set to their population means.
The control variables used in the probit models were
educational degree, medical specialty, and CME partici-
pation date. Geographic region was only provided by
some respondents and was therefore not included in the
analysis. The type of medical practice such as hospital-
based or solo practice was not among the data obtained
by the CME providers.
Partial incomplete responses were included in the ana-
lysis. Having all pre-activity questions left blank was
considered equivalent to nonparticipation, and these en-
tries were excluded. Since the sample size of the distinct
CME activities varied, both the unweighted and weighted
averages of correct responses are reported.
Instrument validation
To assess the extent to which the pre-activity responses
could be generalized among primary care practitioners,the responses were compared across the diverse CME
programs detailed in Table 1.
The scores on pre-activity responses were compared
to self-reported learning in Activities 2–3, where partici-
pants were asked, “Please list one concept or strategy
gained from this activity.”
Participant evaluations of the CME programs were
recorded, to confirm satisfactory evaluations. The rating
of the CME activity on a 1–5 Likert scale is a composite
score which reflects practice relevance and appropriate
teaching level of target population.
Not all participants completed all pre-activity ques-
tions. The data was analyzed both including and exclud-
ing question-specific non-responders, to detect a
potential bias introduced by partial completion.
Activities 2 and 3 were the longest-running programs,
each offered for 13 months. They were analyzed for a
temporal trend, since a news story or regulatory change
during the interval could potentially change practitioner
baseline knowledge or practice patterns.Results
There were 20,705 participants in the combined six
CME activities which spanned 15 months. Each partici-
pant answered one or more of the following questions.Drug indications
See Table 2. For the first question, both the average cor-
rect response rate of 76% and the weighted correct re-
sponse of 79% are within the predicted range. For the
second question, the average correct response rate is
53% (17% below predicted) and the weighted average
correct response rate is 52% (18% below predicted).
Table 2 Responses to multiple choice pre-activity
questions on use of antipsychotic medications
CME activity Activity 2 Activity 3 Activity 4
Sample size n=1237 n=611 n=2400
Responses to: Which of the following is a labeled indication for one or
more atypical antipsychotic drugs?
A. Refractory epilepsy
B. Refractory major depression in adolescents
C. Acute mania associated with bipolar-I disorder
D. Attention deficit/hyperactivity disorder
Incorrect (A) 82 (7%) 40 (6%) 72 (3%)
Incorrect (B) 188 (15%) 92 (15%) 264 (11%)
Correct (C) 912 (74%) 439 (72%) 1992 (83%)
Incorrect (D) 55 (4%) 40 (6%) 72 (3%)
Correct vs. Predicted +4% +2% +13%
Responses to: Which of the following is a labeled indication for an
atypical antipsychotic in a child, 7 years of age?
A. Irritability associated with autism
B. Acute bipolar mania
C. Schizophrenia
D. Generalized anxiety disorder
Correct (A) 777 (63%) 288 (47%) 1152 (48%)
Incorrect (B) 197 (16%) 114 (19%) 456 (19%)
Incorrect (C) 222 (18%) 189 (31%) 720 (30%)
Incorrect (D) 38 (3%) 19 (3%) 72 (3%)
Correct vs. Predicted −7% −23% −22%
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(20% below predicted) and the weighted average is 67%
(18% below predicted).
The participants in Activity 6 were asked: Recom-
mended treatment of autism includes all EXCEPT:
A Correct nutritional deficiencies 6 (12%)
B Treatment of concurrent attention-deficit
hyperactivity disorder 5 (10%)
C Prescribe atypical antipsychotics 29 (57%)
D Use behavioral therapies following early diagnosis
11 (21%)Table 3 Responses to the true-false pre-activity question
on use of antipsychotic medications
CME activity Activity 2 Activity 3
Sample size n=1237 n=611
Responses to: The intramuscular administration of at least one atypical
antipsychotic agent has been approved by the FDA for use in children.
True or false?
Incorrect (True) 341 (28%) 265 (43%)
Correct (False) 896 (72%) 346 (57%)
Correct vs. Predicted −13% −28%The rate of correct response, response C, is 57% (13%
below predicted).Adverse metabolic effects
Participants in Activity 5 were asked to respond to: After
diagnosing Ed with metabolic syndrome, Ed’s doctor ad-
vised him to reduce his weight by 10%, a total of 18
pounds, by diet and exercise. Which of the following
medications potentially makes it more difficult for Ed to
achieve his goal?
A Angiotensin-converting enzyme inhibitors 6667 (41%)
B Diuretic 1243 (8%)
C Vitamin D 1106 (7%)
D Biguanide 7021 (43%)
The rate of correct response, choice B, is 8% (62%
below predicted). Specialty did not predict response to
this question.
Participants in Activity 5 were also asked to respond
to: Within months of being diagnosed with bipolar dis-
order at age 14, Sara gained 20 pounds. Which of the
following is likely to contribute to her recent weight gain
and body mass index of 28?
A Vitamin D deficiency 952 (6%)
B Atypical antipsychotic agent 10349 (63%)
C An eating disorder 1072 (7%)
D Psychostimulant agent 3948 (24%)
The average correct response rate of 63% falls within
the predicted range. Predicted probability of answering
the question correctly given the regression control vari-
ables is 65%. Analysis by specialty indicates that mental
health specialists scored 28% better than average (z=27;
p<0.01), family practitioners scored 14% higher (z=12;
p<0.01), internal medicine specialists scored 9% higher
(z=7; p<0.01), endocrinologists scored 8% higher (z=3;
p<0.01). The regression explains 9% (pseudo-R2=0.09) of
the total variability in responses and was very significant
in predicting scores (LR chi-square=1833; p<0.01).
Table 4 indicates the responses to a pre-activity ques-
tion on adverse drug effects. See Table 5. For the firstTable 4 Responses to the true-false pre-activity question
on adverse drug effects
CME activity Activity 2 Activity 3
Sample size n=1237 n=611
Responses to: Hyperglycemia, hyperlipidemia, and elevated liver
enzymes are labeled side effects for one or more atypical antipsychotics.
True or false?
Correct (True) 1154 (93%) 582 (95%)
Incorrect (False) 83 (7%) 29 (5%)
Correct vs. Predicted +8% +10%
Table 5 Responses to multiple choice pre-activity
questions on adverse drug effects
CME activity Activity 1 Activity 2 Activity 3 Activity 4
Sample size n=39 n=1237 n=611 n=2400
Responses to: Jeff is an athletic 14-year-old who has been diagnosed
with schizophrenia and prescribed an atypical antipsychotic.
You counsel the family about potential cardio-metabolic side effects.
Which risk would you emphasize?
A. Sudden death from myocardial infarction
B. Cardiac arrhythmias
C. Increases in triglycerides, total cholesterol, and low-density
lipoprotein
D. Because patient has normal weight, he is unlikely to experience
significant weight gain
Incorrect (A) n/a 88 (7%) 34 (6%) 120 (5%)
Incorrect (B) n/a 173 (14%) 132 (22%) 408 (17%)
Correct (C) n/a 726 (59%) 288 (47%) 1848 (77%)
Incorrect (D) n/a 245 (20%) 156 (25%) 48 (2%)
Correct vs. Predicted n/a −11% −23% +7%
Responses to: Three months after initiating treatment with antipsychotic
medication, Jeff has blood-work to monitor lipids, liver enzymes,






Incorrect (A) 4 (10%) 144 (12%) 101 (17%) 432 (18%)
Correct (B) 27 (75%) 974 (79%) 443 (73%) 1752 (73%)
Incorrect (C) 3 (8%) 57 (5%) 22 (3%) 72 (3%)
Incorrect (D) 5 (13%) 55 (4%) 44 (7%) 144 (6%)
Correct vs. Predicted +5% +9% +3% +3%
Table 6 Responses to the pre-activity question on vulnerable
CME activity Activity 1 Activity 2
Sample size n=45 n=1237
Responses to: Mental illness shortens lifespan as follows:
A. Patients with mental illness die 25 years earlier than the general pop
B. The average 15 years of potential life lost can be explained by premature
C. The causes of mortality are similar to the general population, but occur 10
D. Suicide and accidents including motor vehicle accidents account for most
Correct (A) 13 (29%) 629 (51%)
Incorrect (B) 9 (20%) 285 (23%)
Next best answer (C) 20 (44%) 265 (21%)
Incorrect (D) 3 (7%) 55 (5%)
Correct vs. Predicted −41% −19%
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a weighted correct response average of 67%. For the sec-
ond question, the average correct response rate was 75%
with a weighted average also of 75%. These are within
the predicted range.
Patients at increased risk
Responses to a question about vulnerable populations
are presented in Table 6. The average correct response
rate is 36% (34% below predicted) with a weighted aver-
age of 33% (37% below predicted).
Figure 1 illustrates the correct responses compared to
the predicted responses for the pre-activity question on
mental illness and chronic disease risk. The responses
are presented across CME activities 1–5. Standard error
bars are shown. Since one of the three incorrect re-
sponses (Choice C) in the question was close to the cor-
rect answer, it may reflect a stronger knowledge base
than the other two incorrect choices. We therefore in-
cluded this response in the figure.
Activity 5’s large sample size allowed for further ana-
lysis. Participants had a predicted probability of 31% in
answering correctly. Participants specializing in mental
health scored 14% higher than average (z=11; p<0.01)
and family practitioners scored 4% higher (z=3; p<0.05).
The probit regression explained 1% (pseudo-R2=0.01) of
the total variability in the responses and was significant
(LR chi-square=202, p<0.01).
Drug safety updates
Participants in Activity 5 were asked to respond to: Which
of the following statements is correct?
A. Comparative effectiveness trials are part of the drug
approval process [5622 (34%)]
B. Phase 3 clinical trials are powered to identify appetite-
stimulating effects of medication [3346 (20%)]populations
Activity 3 Activity 4 Activity 5
N=611 n=2400 n=16361
ulation, mostly due to earlier onset of chronic medical conditions.
death early in life.
years earlier on average.
of the 10 years of shorter life expectancy.
215 (35%) 840 (35%) 5166 (32%)
184 (30%) 144 (6%) 1584 (10%)
169 (28%) 528 (22%) 4557 (28%)





































Continuing medical education program
Figure 1 Responses to pre-activity question on chronic disease
risk in mental illness.
Table 7 Responses to pre-activity questions on drug
safety information
CME activity Activity 2 Activity 3
Sample size n=1237 n=611
Responses to: Practitioners are asked to report drug adverse events:
A. To MedWatch
B. Only when the adverse event is not specified on the drug label
C. Within 30 days of occurrence, as required by law.
D. Voluntarily, if observed within 30 days of the first dose
Correct (A) 698 (56%) 237 (39%)
Incorrect (B) 85 (7%) 53 (9%)
Incorrect (C) 203 (10%) 174 (29%)
Incorrect (D) 243 (20%) 146 (24%)
Correct vs. Predicted −14% −31%
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passive adverse events reporting system [4424 (27%)]
D. Current legislation requires clinical trials in pediatric
populations [2452 (15%)]
On average, 15% of participants answered correctly
(55% below predicted) selecting choice D. Predicted
probability of answering correctly given the regression
variables is 14%. Analysis by specialty indicates that pe-
diatricians scored 7% higher than average (z=6; p<0.01)
and mental health specialists scored 2% higher (z=2;
p<0.02). General practitioners scored 3% below average
(z=−2; p<0.03) and emergency medicine specialists scored
4% lower (z=−2; p<0.04). The regression explained 2% of
the total variability in answers (pseudo-R2=0.02) and was
very significant (LR chi-square=242; p<0.01).
Note that this question had the highest non-response
rate, with 517 (3%) of participants leaving the question
blank. Regression analysis excluding non-responders had
the same significant outcome variables as the analysis
which included non-responders.
See Table 7. The average correct response was 47%
(23% below predicted) and the weighted average was 51%
(19% below predicted).
For Activity 5 (n=16,361), the top three professions of
participants were nurse practitioners (52%, n=8407),
physicians (38%, n=6212), and physician assistants (3%,
n=476). The top specialties were psychiatry/mental
health (12%, n=2022), family medicine (11%, n=1875),
internal medicine (10%, n=1639), general practice (6%,
n=946), and pediatrics (6%, n=906).
We controlled the regression analysis for predicting
correct pre-activity responses for specialty, professionaldegree, and date of CME participation by quartile. The
time of participation was included in the regression ana-
lysis because it explained a significant portion of the
variability but yielded no clear pattern for interpretation.
Results of the regression analysis follow each applicable
question. The results of the analysis by specialty concur
with the practice demands of each specialty. For ex-
ample, family physicians, practitioners who follow pa-
tients across the lifespan, were more likely to correctly
identify the profound extent to which mental illness
shortens life expectancy due to chronic diseases.
Instrument analysis
The strength of the instrument is its ease of use in the
context of CME programming, and its associated ability
to identify trends in practitioner knowledge and some
broad comparisons among practitioners. However since
the instrument is comprised of multiple choice ques-
tions, responses to any one question are more appropri-
ately viewed in the context of the full instrument.
In order to assess the variability of the instrument, re-
sponses were compared across CME programs which
varied in content, timeframe, recruitment, and question
administration. Figure 1 depicts the responses. Re-
sponses among CME programs varied within the pre-
established +/−10% test error, except for one program
with a small sample size. The unweighted, correct re-
sponse averages across CME programs are reported.
To assess the extent to which recruitment methods
may influence the pre-activity responses, the overall
scores of the two Audio-Digest programs were com-
pared. The two programs differ only in how the partici-
pants were recruited. They were recruited as either,
subscribers or one-time participants. The 10% difference
in responses falls within the pre-established test error.
Practice-relevance and the perception of the CME pro-
gram’s usefulness were considered in the instrument
Kohlstadt and Wharton Nutrition Journal 2013, 12:44 Page 7 of 9
http://www.nutritionj.com/content/12/1/44analysis. The participants in each of the 6 activities were
asked to evaluate the program on a 1–5 Likert scale, 5
being the highest score. The ratings for each program
ranged from 4.0 to 5.0, with an unweighted mean score
of 4.5, suggesting that all were well-received and applic-
able to participants’ clinical practice.
The pre-activity question responses were correlated
with what participants said they learned from the acti-
vity. Participants in Activities 2 and 3 were asked to
“Please list one concept or strategy gained from this ac-
tivity.” The written responses fell into categories consist-
ent with pre-activity responses: Pediatric indications
(20), patient adherence (2), adverse effects (71),
MedWatch reporting (9), drug interactions (5), and pa-
tient risk factor (8).
A temporal trend in correct responses was not ob-
served between the first three months and the total 13
months of the responses to Activities 2 and 3. Neither
was any single news event or regulatory change identi-
fied which might be anticipated to influence practitioner
knowledge on this topic during the study period.
Discussion
The childhood obesity epidemic is recent; however, prac-
titioners who care for children appear as familiar with
adverse metabolic drug effects as practitioners who care
for adults. Those specializing in pediatrics performed
better on a question about drug research, perhaps
reflecting recent educational activities directed towards
pediatricians.
Across medical specialties practitioner knowledge of
medication-related weight gain was low in four areas of
our study. Each of the knowledge gaps if practice rele-
vant, would overestimate the medication’s benefits or
underestimate adverse metabolic effects. The net effect
of each knowledge gap would therefore affect clinical
decision-making in the same direction, potentially con-
tributing to excess metabolic dysfunction. The four areas
of low practitioner knowledge are as follows:
Responses to questions about drug indications and
the use of antipsychotics in autism suggest that some
practitioners may mistake the management of
aggressive symptoms for treatment of the underlying
disease process. Additionally, new oral preparations
are available for children who have difficulty
swallowing pills. These preparations should be used
before prescribing intramuscular preparations, which
have greater metabolic effects and do not have
pediatric use indications at the time this manuscript
is written.Among the questions pertaining to adverse metabolic
effects, only 8% of practitioners selected the intendedresponse that some diuretics have been associated
with promoting insulin resistance. The 41% who
incorrectly selected “angiotensin-converting enzyme
inhibitors” are unlikely to have been aware that some
diuretics promote insulin resistance and angiotensin
converting enzymes, in contrast, may be insulin
sensitizing [15], the distinction between these two
antihypertensive therapies in a patient with metabolic
syndrome would be practice relevant. Furthermore,
these respondents may have erroneously equated the
reduction in peripheral edema with meaningful, long-
term weight loss among their patients. The 43% of
practitioners who incorrectly selected “biguanide” may
not have realized that metformin is in this medication
class, so the response would have been more
informative if the answer had read “biguanide
(metformin).”Responses reflected low baseline knowledge of drug
safety research and MedWatch, a passive surveillance
program. It is possible that practitioners lack a
framework for managing the escalating drug-related
information. Our findings parallel those of a recent
study of physician knowledge and adverse events
reporting of dietary supplements [16].Mental illness is associated with increased
vulnerability to adverse metabolic effects. The
profound chronic disease mortality among patients
with mental illness was under-recognized across
specialties as measured by our instrument. Awareness
of the high mortality from chronic diseases among
patients with mental illness might be unlikely to cause
practitioners to alter the patient’s psychiatric
medications; however, it would guide overall care such
as screening, referring, concurrent medication
prescribing, and managing co-morbidities.
The knowledge gaps parallel the few peer-reviewed
publications on medication-related weight gain, other
than the atypical antipsychotics. Reviewing the proceed-
ing of a large international conference on obesity [17]
revealed a similar paucity of research and translational
initiatives surrounding medication-related weight gain.
Additionally, current drug product information and la-
beling lacks a consistent format or location for commu-
nicating the potential effects of a drug on the patient’s
appetite and underlying metabolism.
Practitioners were familiar with the general indications
for use of atypical antipsychotics in children and the ad-
verse metabolic effects including prolactinemia, dyslip-
idemia, elevated liver enzymes, insulin resistance, and
weight gain, findings which correlate with the lay and
medical literature’s recent attention to the topic [4].
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ing have been directed to pediatricians and pediatricians
were more knowledgeable than other practitioners about
ongoing pharmacovigilance.
The instrument demonstrated internal consistency
across diverse CME programs (Table 1), suggesting the
findings may appropriately be generalized across U.S.
primary care practitioners. The sampling frame captures
participants across the United States, with diverse pa-
tient populations in diverse practice settings. The degrees
of the participants, nurse practitioners, physician assis-
tants, and medical doctors, correctly represent the educa-
tional diversity of primary care practitioners. Pediatricians
scored as well as their adult medicine counterparts,
suggesting that future initiatives could appropriately be di-
rected to all primary care practitioners.
Additional merits of the instrument are that it can be
implemented in a timely and cost-sensitive way. It can
be applied to assess evidence-based practice knowledge
[18]. Study findings can provide baseline data, by which
to gauge the effectiveness of future interventions. The
instrument also provides a continuing education curricu-
lum developed free of industry interests. An internet
curriculum on safe medication use measurably improved
clinician practice choices [19,20].
Knowledge is one of many clinical practice barriers to
modifying medication-related weight gain, and merits in-
corporation into future initiatives. The findings, taken
with the population prevalence of obesity, the emerging
treatment options, and the central role of the primary care
practitioner, suggest a significant prevention opportunity.
Conclusions
Pediatricians’ knowledge base of adverse metabolic drug
effects appears comparable to their counterparts in adult
medicine. Regardless of medical specialty, practitioners
participating in the CME programs reflected low know-
ledge on specific questions pertaining to drug indications,
adverse metabolic effects, patient risk profiles and safety
updates. Each of the four knowledge gaps would poten-
tially influence clinical decision-making in the same man-
ner, leading clinicians to overestimate the benefits of a
drug in relation to its metabolic risks. Therefore future ef-
forts to detail cross-specialty practitioner knowledge of
metabolic drug effects and initiate education strategies to
bolster knowledge could meaningfully contribute to obes-
ity prevention.
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